Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014 | 0.85 | GP6 (0.66) | GP6PPARGAGTR1AGTR2 | |
| SCHEMBL986459 | 0.84 | AGTR1 (0.49) | APLNRPPARGAGTR1AGTR2 | |
| SCHEMBL10535992 | 0.78 | GP6 (0.59) | GP6PPARGAGTR1AGTR2 | |
| SCHEMBL21083688 | 0.78 | GP6 (0.59) | GP6PPARGAGTR1AGTR2 | |
| SCHEMBL17949543 | 0.77 | PPARG (0.57) | GP6PPARGAGTR1AGTR2ACHE | |
| SCHEMBL3459616 | 0.77 | PPARG (0.59) | GP6PPARGAGTR1AGTR2ACHE | |
| SCHEMBL21083964 | 0.76 | GP6 (0.56) | GP6PPARGAGTR1AGTR2 | |
| SCHEMBL9016503 | 0.75 | AGTR1 (0.48) | APLNRPPARGAGTR1AGTR2ACHE | |
| SCHEMBL3872809 | 0.75 | AGTR1 (0.51) | GP6AGTR1AGTR2 | |
| SCHEMBL9016466 | 0.75 | APLNR (0.44) | APLNRPPARGAGTR1AGTR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868180-B2 | Process for the preparation of sartan derivatives and intermediates useful in such process | KRKA, D.D. NOVO MESTO (SI) | 2011-01-11 | — | — | US | disclosed |
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | KRKA, D.D. NOVO MESTO (SK) | 2008-12-18 | — | — | US | disclosed |
| EP-1764365-A1 | A process for the preparation of sartan derivates and intermediates useful in such process | KRKA, D.D., Novo Mesto (SI) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312451-A1 | Process For the Preparation of Sartan Derivatives and Intermediates Useful in Such Process | MC5R, NPY5R, ADRA1D | GP6 137/4885APLNR 1586/4885PPARG 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.